Hypothesis

We hypothesize that individual differences in pain tolerance are driven by the NAD+-dependent activity of SIRT1 in peripheral nociceptors, which modulates mitochondrial ROS production and inflammasome NLRP3 activation. Higher nociceptor SIRT1 activity preserves mitochondrial fidelity, reduces pro‑inflammatory signaling, and raises pain thresholds, thereby aligning with slower epigenetic aging. Conversely, low SIRT1 activity leads to mitochondrial dysfunction, increased NLRP3‑mediated IL‑1β release, and sensitized nociceptors, manifesting as reduced pain tolerance and accelerated GrimAge/DunedinPoAm scores.

Mechanistic Rationale

1. NAD+–SIRT1 axis in nociceptors – SIRT1 deacetylates PGC‑1α and FOXO3a, promoting mitochondrial biogenesis and antioxidant defenses. In dorsal root ganglion (DRG) neurons, SIRT1 activation suppresses NLRP3 inflammasome assembly by deacetylating the NLRP3 protein, limiting caspase‑1 cleavage and IL‑1β maturation.[4]
2. Mitochondrial ROS as a pain sensitizer – Elevated mtROS sensitizes TRPA1 and Nav1.8 channels, lowering heat pain thresholds.[5] Reduced SIRT1 activity exacerbates mtROS, creating a feed‑forward loop of nociceptor hyperexcitability.
3. Inflammaging link – NLRP3‑derived IL‑1β contributes to systemic inflammaging, a known driver of epigenetic age acceleration measured by GrimAge.[1] Thus, nociceptor‑specific SIRT1 deficiency may amplify circulating inflammatory mediators that accelerate epigenetic clocks.
4. Vagal tone modulation – Enhanced vagal afferent signaling increases acetylcholine release in the DRG, which activates α7‑nicotinic receptors and boosts NAD+ synthesis via NAMPT, indirectly supporting SIRT1 activity.[3] This connects the observed vagal‑pain tolerance relationship to the proposed mitochondrial mechanism.

Testable Predictions

• Prediction 1: Individuals with higher baseline heat pain thresholds will exhibit greater SIRT1 protein expression and activity in isolated DRG neurons (or surrogate peripheral blood mononuclear cells adjusted for neuronal enrichment) compared with low‑tolerance individuals.
• Prediction 2: Ex vivo SIRT1 inhibition (using EX‑527) in DRG cultures from high‑tolerance donors will increase mtROS, NLRP3 activation, and IL‑1β release, while decreasing pain‑related gene expression (e.g., SCN9A, TRPV1).
• Prediction 3: Oral supplementation with nicotinamide riboside (NR) to raise systemic NAD+ for 8 weeks will increase pain tolerance (measured by quantitative sensory testing) and reduce GrimAge acceleration in middle‑aged adults with baseline low tolerance.
• Prediction 4: The analgesic effect of NR will be attenuated in participants receiving a selective SIRT1 inhibitor (e.g., via a short‑term oral EX‑527 course), confirming SIRT1 dependence.

Experimental Design

A double‑blind, placebo‑controlled RCT with 120 participants aged 45‑65, stratified by baseline pain tolerance (low vs. high). Arms: (1) NR 1 g/day, (2) NR + EX‑527 low dose, (3) placebo, (4) placebo + EX‑527. Primary outcomes: change in heat pain threshold (Δ°C) and ΔGrimAge at week 8. Secondary outcomes: DRG‑derived SIRT1 activity (via ex vivo assay), plasma IL‑1β, mtROS in PBMCs, and vagal tone (HF‑HRV).

Falsifiability

If NR fails to improve pain tolerance or epigenetic age irrespective of SIRT1 inhibition, or if SIRT1 activity shows no correlation with baseline pain thresholds, the hypothesis would be falsified. Similarly, if EX‑527 does not abolish NR‑induced improvements, the proposed SIRT1‑mediated mechanism would be unsupported.

Implications

Establishing pain tolerance as a functional readout of nociceptor mitochondrial NAD+‑SIRT1 health would provide a rapid, low‑cost phenotype for tracking biological age and evaluating geroprotective interventions that target mitochondrial inflammation.

References

[1] https://pubmed.ncbi.nlm.nih.gov/38855906/ [2] https://pmc.ncbi.nlm.nih.gov/articles/PMC6710702/ [3] https://pmc.ncbi.nlm.nih.gov/articles/PMC7296181/ [4] https://pmc.ncbi.nlm.nih.gov/articles/PMC11424521/ [5] https://pmc.ncbi.nlm.nih.gov/articles/PMC8391112/ [6] https://news.osu.edu/brain-changes-behind-pain-sensitivity-may-affect-older-women-more/ [7] https://pmc.ncbi.nlm.nih.gov/articles/PMC12670344/